Caliway Biopharmaceuticals Co. L
6919
Ранг среди акций
#4342
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Цена акции
$2.29
Рыночная капитализация
$3.56B
Изменение (1 день)
-2.50%
Изменение (1 год)
-57.22%
Страна
TW
Торговля Caliway Biopharmaceuticals Co. L (6919)
Категория
Healthcare
EPS для Caliway Biopharmaceuticals Co. L (6919)
EPS по состоянию на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Caliway Biopharmaceuticals Co. L, текущий EPS компании (TTM) составляет 0. В конце 2026 EPS компании составлял 0, равна показателю 2026 года, равному 0.
История EPS компании Caliway Biopharmaceuticals Co. L с 2019 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2025 | $-0.01 | -41.60% |
| 2024 | $-0.01 | -1.57% |
| 2023 | $-0.01 | 62.82% |
| 2022 | $-0.01 | -10.34% |
| 2021 | $-0.01 | 89.13% |
| 2020 | 0.00 | -19.30% |
| 2019 | $-0.01 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
